Array BioPharma shares climb on more solid trial results
BOULDER — Cancer-drug developer Array BioPharma Inc. (Nasdaq: ARRY) saw its share price zip upward more than 6 percent Wednesday after the company released positive results from its Phase 3 clinical trial looking at the use of binimetinib and encorafenib in the treatment of melanoma.
Boulder-based Array announced the results jointly with French drugmaker Pierre Fabre. The two companies inked a deal last year to globally develop and commercialize binimetinib and encorafenib.
Array’s Columbus trial is looking at the combination of binimetinib and encorafenib in the treatment of BRAF-mutant melanoma versus treatment with vemurafenib, a drug already on the market. Array’s combination…
THIS ARTICLE IS FOR SUBSCRIBERS ONLY
Continue reading for less than $3 per week!
Get a month of award-winning local business news, trends and insights
Access award-winning content today!